Cryopreserved Arterial Allografts and ABO and Rhesus Compatibility

详细信息    查看全文

• 作者：Nellie Della Schiava¹ ; ² ; ^{dellaschiava.nellie@neuf.fr" class="auth_mail" title="E-mail the corresponding author} ; Jean-Louis Mathevet¹ ; ² ; Tarek Boudjelit¹ ; Matthieu Arsicot¹ ; ² ; Patrick Feugier¹ ; ² ; Patrick Lermusiaux¹ ; ² ; Antoine Millon¹ ; ²
• 刊名：Annals of Vascular Surgery
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：33
• 期：Complete
• 页码：173-180
• 全文大小：425 K

文摘

Arterial cryopreserved allografts are conduit of choice for arterial bypass in case of infection. They are sometimes submitted to accelerated degeneration: stenosis, thrombosis, or aneurysmal evolution. We hypothesized that ABO group and Rhesus compatibility could play a role in arterial cryopreserved allograft complications.

Methods

Patients who benefit from allograft bypass from 2006 to 2011 were retrospectively compared, regarding ABO or rhesus compatibility and irregular agglutinins.

Results

Seventy-two patients were included. Regarding ABO mismatch, there was no difference in terms of death (51% vs. 43%, P = 0.820), thrombosis (25% vs. 32%, P = 0.78), rupture (9% vs. 0%, P = 0.247), stenosis (3% vs. 12%, P = 0.331), aneurysmal degeneration (16% vs. 12%, P = 1), and 5 years of secondary patency rate (34% vs. 39%, P = 0.141). There was also no difference regarding Rhesus mismatch.

Conclusions

Allograft degeneration does not seem to be related to ABO mismatch. This degeneration could be related to another way of immunogenicity, particularly Human Leukocyte Antigen mismatch, and needs further exploration.